Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 198539, 10 pages
http://dx.doi.org/10.1155/2014/198539
Review Article

Immunological Dysregulation in Multiple Myeloma Microenvironment

1Department of Clinical and Molecular Biomedicine, Haematology Section, University of Catania, Catania, Italy
2Fondazione Veronesi, Roma, Italy
3Division of Hematology, AOU “Policlinico-Vittorio Emanuele”, Catania, Italy

Received 11 April 2014; Accepted 20 May 2014; Published 11 June 2014

Academic Editor: Lijun Jia

Copyright © 2014 Alessandra Romano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. V. Rajkumar and F. Buadi, “Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation,” Best Practice and Research: Clinical Haematology, vol. 20, no. 4, pp. 665–680, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. O. Landgren and N. Korde, “Multiple myeloma precursor disease: current clinical and epidemiological insights and future opportunities,” Oncology, vol. 25, no. 7, pp. 589–590, 2011. View at Google Scholar · View at Scopus
  3. O. Landgren, R. A. Kyle, R. M. Pfeiffer et al., “Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study,” Blood, vol. 113, no. 22, pp. 5412–5417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Brousseau, X. Leleu, J. Gerard et al., “Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients,” Clinical Cancer Research, vol. 13, no. 20, pp. 6026–6031, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Chiecchio, G. P. Dagrada, A. H. Ibrahim et al., “Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context,” Haematologica, vol. 94, no. 12, pp. 1708–1713, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Agarwal and I. M. Ghobrial, “Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease,” Clinical Cancer Research, vol. 19, no. 5, pp. 985–994, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. A. Fowler, G. R. Mundy, S. T. Lwin, and C. M. Edwards, “Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1,” Cancer Research, vol. 72, no. 9, pp. 2183–2189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Nefedova, T. H. Landowski, and W. S. Dalton, “Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms,” Leukemia, vol. 17, no. 6, pp. 1175–1182, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. V. Hughes, “Microenvironment: neighbourhood watch,” Nature, vol. 480, no. 7377, pp. S48–S49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. C. S. Mitsiades, K. C. Anderson, and D. R. Carrasco, “Mouse models of human myeloma,” Hematology/Oncology Clinics of North America, vol. 21, no. 6, pp. 1051–1069, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. Z.-W. Li and W. S. Dalton, “Tumor microenvironment and drug resistance in hematologic malignancies,” Blood Reviews, vol. 20, no. 6, pp. 333–342, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. J. W. Croese, C. M. vas Nunes, J. Radl, M. H. M. Van Den Enden-Vieveen, R. J. Brondijk, and W. J. A. Boersma, “The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow,” British Journal of Cancer, vol. 56, no. 5, pp. 555–560, 1987. View at Google Scholar · View at Scopus
  13. K. Vanderkerken, H. De Raeve, E. Goes et al., “Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse,” British Journal of Cancer, vol. 76, no. 4, pp. 451–460, 1997. View at Google Scholar · View at Scopus
  14. R. A. Campbell, S. J. Manyak, H. H. Yang et al., “LAGλ1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma,” International Journal of Oncology, vol. 28, no. 6, pp. 1409–1417, 2006. View at Google Scholar · View at Scopus
  15. A. L. Kovalchuk, J. S. Kim, S. S. Park et al., “IL-6 transgenic mouse model for extraosseous plasmacytoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 3, pp. 1509–1514, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. R. LeBlanc, L. P. Catley, T. Hideshima et al., “Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model,” Cancer Research, vol. 62, no. 17, pp. 4996–5000, 2002. View at Google Scholar · View at Scopus
  17. S. Yaccoby, B. Barlogie, and J. Epstein, “Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations,” Blood, vol. 92, no. 8, pp. 2908–2913, 1998. View at Google Scholar · View at Scopus
  18. S. Yaccoby and J. Epstein, “The proliferative potential of myeloma plasma cells manifest in the SCID-hu host,” Blood, vol. 94, no. 10, pp. 3576–3582, 1999. View at Google Scholar · View at Scopus
  19. M. Z. Dewan, M. Watanabe, K. Terashima et al., “Prompt tumor formation and maintenance of constitutive NF-κB activity of multiple myeloma cells in NOD/SCID/γcnull mice,” Cancer Science, vol. 95, no. 7, pp. 564–568, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Miyakawa, Y. Ohnishi, M. Tomisawa et al., “Establishment of a new model of human multiple myeloma using NOD/SCID/γcnull (NOG) mice,” Biochemical and Biophysical Research Communications, vol. 313, no. 2, pp. 258–262, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Tassone, P. Neri, D. R. Carrasco et al., “A clinically relevant SCID-hu in vivo model of human multiple myeloma,” Blood, vol. 106, no. 2, pp. 713–716, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Yata and S. Yaccoby, “The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells,” Leukemia, vol. 18, no. 11, pp. 1891–1897, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Calimeri, E. Battista, F. Conforti et al., “A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells,” Leukemia, vol. 25, no. 4, pp. 707–711, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Su, L. Zhang, W. Zhang et al., “Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling,” PloS ONE, vol. 9, no. 1, Article ID e85059, 2014. View at Google Scholar
  25. R. W. J. Groen, W. A. Noort, R. A. Raymakers et al., “Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma,” Blood, vol. 120, no. 3, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. G. W. Basak, A. S. Srivastava, R. Malhotra, and E. Carrier, “Multiple myeloma bone marrow niche,” Current Pharmaceutical Biotechnology, vol. 10, no. 3, pp. 335–346, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Manier, A. Sacco, X. Leleu, I. M. Ghobrial, and A. M. Roccaro, “Bone marrow microenvironment in multiple myeloma progression,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 157496, 5 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Iriuchishima, K. Takubo, Y. Miyakawa et al., “Neovascular niche for human myeloma cells in immunodeficient mouse bone,” PloS ONE, vol. 7, no. 2, Article ID e30557, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Hideshima, H. Ikeda, D. Chauhan et al., “Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells,” Blood, vol. 114, no. 5, pp. 1046–1052, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Hideshima, K. Podar, D. Chauhan, and K. C. Anderson, “Cytokines and signal transduction,” Best Practice and Research: Clinical Haematology, vol. 18, no. 4, pp. 509–524, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Kim, S.-Y. Kong, M. Fulciniti et al., “Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo,” British Journal of Haematology, vol. 149, no. 4, pp. 537–549, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Podar, D. Chauhan, and K. C. Anderson, “Bone marrow microenvironment and the identification of new targets for myeloma therapy,” Leukemia, vol. 23, no. 1, pp. 10–24, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Podar, P. G. Richardson, T. Hideshima, D. Chauhan, and K. C. Anderson, “The malignant clone and the bone-marrow environment,” Best Practice and Research in Clinical Haematology, vol. 20, no. 4, pp. 597–612, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. Y.-T. Tai, M. Fulciniti, T. Hideshima et al., “Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis,” Blood, vol. 110, no. 5, pp. 1656–1663, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Hideshima, D. Chauhan, P. Richardson et al., “NF-κB as a therapeutic target in multiple myeloma,” Journal of Biological Chemistry, vol. 277, no. 19, pp. 16639–16647, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Moreaux, E. Legouffe, E. Jourdan et al., “BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone,” Blood, vol. 103, no. 8, pp. 3148–3157, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Conticello, R. Giuffrida, L. Adamo et al., “NF-κB localization in multiple myeloma plasma cells and mesenchymal cells,” Leukemia Research, vol. 35, no. 1, pp. 52–60, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Podar, “Novel targets and derived small molecule inhibitors in multiple Myeloma,” Current Cancer Drug Targets, vol. 12, no. 7, pp. 797–813, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Zipori, “The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell,” Cancer Microenvironment, vol. 3, no. 1, pp. 15–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Balakumaran, P. G. Robey, N. Fedarko, and O. Landgren, “Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis,” Expert Review of Molecular Diagnostics, vol. 10, no. 4, pp. 465–480, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Podar and K. C. Anderson, “Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies,” Current Cancer Drug Targets, vol. 11, no. 9, pp. 1005–1024, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Fan, A. Schimming, D. Jaeger, and K. Podar, “Targeting the tumor microenvironment: focus on angiogenesis,” Journal of Oncology, vol. 2012, Article ID 281261, 16 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Kumar, M. A. Gertz, A. Dispenzieri et al., “Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy,” Bone Marrow Transplantation, vol. 34, no. 3, pp. 235–239, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. F. di Raimondo, M. P. Azzaro, G. A. Palumbo et al., “Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood,” Haematologica, vol. 85, no. 8, pp. 800–805, 2000. View at Google Scholar · View at Scopus
  45. J. Hu, E. van Valckenborgh, E. Menu, E. de Bruyne, and K. Vanderkerken, “Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models,” Disease Models and Mechanisms, vol. 5, no. 6, pp. 763–771, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Kim, R. A. Denu, B. A. Dollar et al., “Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells,” British Journal of Haematology, vol. 158, no. 3, pp. 336–346, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. T. W. Wong, H. Kita, C. A. Hanson, D. K. Walters, B. K. Arendt, and D. F. Jelinek, “Induction of malignant plasma cell proliferation by eosinophils,” PloS ONE, vol. 8, no. 7, Article ID e70554, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Pratt, O. Goodyear, and P. Moss, “Immunodeficiency and immunotherapy in multiple myeloma,” British Journal of Haematology, vol. 138, no. 5, pp. 563–579, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Rossi, C. Botta, P. Correale, P. Tassone, and P. Tagliaferri, “Immunologic microenvironment and personalized treatment in multiple myeloma,” Expert Opinion on Biological Therapy, vol. 13, no. 1, supplement, pp. S83–S93, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. D. J. Chung, M. Rossi, E. Romano et al., “Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells,” Blood, vol. 114, no. 3, pp. 555–563, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Mahnke, S. Ring, T. S. Johnson et al., “Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation,” European Journal of Immunology, vol. 37, no. 8, pp. 2117–2126, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. J. R. Nair, C. H. Rozanski, and K. P. Lee, “Under one roof: the bone marrow survival niche for multiple myeloma and normal plasma cells,” Oncoimmunology, vol. 1, no. 3, pp. 388–389, 2012. View at Google Scholar
  53. A. Sharma, R. Khan, S. Joshi, L. Kumar, and M. Sharma, “Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma,” Leukemia & Lymphoma, vol. 51, no. 5, pp. 920–927, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. Z. Chen, F. Lin, Y. Gao et al., “FOXP3 and RORγt: transcriptional regulation of Treg and Th17,” International Immunopharmacology, vol. 11, no. 5, pp. 536–542, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Q. Crome, A. Y. Wang, and M. K. Levings, “Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease,” Clinical and Experimental Immunology, vol. 159, no. 2, pp. 109–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. B. Hoechst, J. Gamrekelashvili, M. P. Manns, T. F. Greten, and F. Korangy, “Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells,” Blood, vol. 117, no. 24, pp. 6532–6541, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. I. Kryczek, M. Banerjee, P. Cheng et al., “Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments,” Blood, vol. 114, no. 6, pp. 1141–1149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. K. Lee, R. Mukasa, R. D. Hatton, and C. T. Weaver, “Developmental plasticity of Th17 and Treg cells,” Current Opinion in Immunology, vol. 21, no. 3, pp. 274–280, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Schmidl, L. Hansmann, R. Andreesen, M. Edinger, P. Hoffmann, and M. Rehli, “Epigenetic reprogramming of the RORC locus during in vitro expansion is a distinctive feature of human memory but not naïve Treg,” European Journal of Immunology, vol. 41, no. 5, pp. 1491–1498, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. B. Maecker, K. S. Anderson, M. S. von Bergwelt-Baildon et al., “Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma,” British Journal of Haematology, vol. 121, no. 6, pp. 842–848, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. G. Görgün, E. Calabrese, E. Soydan et al., “Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma,” Blood, vol. 116, no. 17, pp. 3227–3237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. D. E. Joshua, R. D. Brown, P. J. Ho, and J. Gibson, “Regulatory T cells and multiple myeloma,” Clinical Lymphoma and Myeloma, vol. 8, no. 5, pp. 283–286, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Laronne-Bar-On, D. Zipori, and N. Haran-Ghera, “Increased regulatory versus effector T cell development is associated with thymus atrophy in mouse models of multiple myeloma,” Journal of Immunology, vol. 181, no. 5, pp. 3714–3724, 2008. View at Google Scholar · View at Scopus
  64. S. Feyler, M. Von Lilienfeld-Toal, S. Jarmin et al., “CD4+CD25+FoxP3+ regulatory T cells are increased whilst CD3+CD4CD8αβTCR+ Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden,” British Journal of Haematology, vol. 144, no. 5, pp. 686–695, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. R. Gupta, P. Ganeshan, M. Hakim, R. Verma, A. Sharma, and L. Kumar, “Significantly reduced regulatory T cell population in patients with untreated multiple myeloma,” Leukemia Research, vol. 35, no. 7, pp. 874–878, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. R. H. Prabhala, P. Neri, J. E. Bae et al., “Dysfunctional T regulatory cells in multiple myeloma,” Blood, vol. 107, no. 1, pp. 301–304, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Beyer, S. Classen, E. Endl et al., “Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3,” Clinical and Developmental Immunology, vol. 2011, Article ID 734036, 12 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Favaloro, R. Brown, E. Aklilu et al., “Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state,” Leukemia & Lymphoma, 2013. View at Google Scholar
  69. R. H. Prabhala, D. Pelluru, M. Fulciniti et al., “Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma,” Blood, vol. 115, no. 26, pp. 5385–5392, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. K. Noonan, L. Marchionni, J. Anderson, D. Pardoll, G. D. Roodman, and I. Borrello, “A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma,” Blood, vol. 116, no. 18, pp. 3554–3563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Bryant, H. Suen, R. Brown et al., “Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance,” Blood Cancer Journal, vol. 3, article e148, 2013. View at Google Scholar
  72. C.-J. Shen, Z.-H. Yuan, Y.-X. Liu, and G.-Y. Hu, “Increased numbers of T helper 17 cells and the correlation with clinicopathological characteristics in multiple myeloma,” Journal of International Medical Research, vol. 40, no. 2, pp. 556–564, 2012. View at Google Scholar · View at Scopus
  73. K. M. Dhodapkar, S. Barbuto, P. Matthews et al., “Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma,” Blood, vol. 112, no. 7, pp. 2878–2885, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. G. Adhikary, D. Grun, C. Kerr et al., “Identification of a population of epidermal squamous cell carcinoma cells with enhanced potential for tumor formation,” PloS ONE, vol. 8, no. 12, Article ID e84324, 2013. View at Google Scholar
  75. S. J. Coles, E. C. Y. Wang, S. Man et al., “CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia,” Leukemia, vol. 25, no. 5, pp. 792–799, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. H. Olteanu, A. M. Harrington, P. Hari, and S. H. Kroft, “CD200 expression in plasma cell myeloma,” British Journal of Haematology, vol. 153, no. 3, pp. 408–411, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. G. A. Palumbo, N. Parrinello, G. Fargione et al., “CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia,” Leukemia Research, vol. 33, no. 9, pp. 1212–1216, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. F. Talebian and X. F. Bai, “The role of tumor expression of CD200 in tumor formation, metastasis and susceptibility to T lymphocyte adoptive transfer therapy,” Oncoimmunology, vol. 1, no. 6, pp. 971–973, 2012. View at Google Scholar
  79. R. M. Gorczynski, Z. Chen, S. Shivagnahnam et al., “Potent immunosuppression by a bivalent molecule binding to CD200R and TGF-βR,” Transplantation, vol. 90, no. 2, pp. 150–159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. D. Alapat, J. Coviello-Malle, R. Owens et al., “Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma,” American Journal of Clinical Pathology, vol. 137, no. 1, pp. 93–100, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Moreaux, D. Hose, T. Reme et al., “CD200 is a new prognostic factor in multiple myeloma,” Blood, vol. 108, no. 13, pp. 4194–4197, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. C. Conticello, R. Giuffrida, N. Parrinello et al., “CD200 expression in patients with Multiple Myeloma: another piece of the puzzle,” Leukemia Research, vol. 37, no. 12, pp. 1616–1621, 2013. View at Google Scholar
  83. S. Preston, G. J. Wright, K. Starr, A. N. Barclay, and M. H. Brown, “The leukocyte/neuron cell surface antigen OX2 binds to a ligand on macrophages,” European Journal of Immunology, vol. 27, no. 8, pp. 1911–1918, 1997. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Nagaraj, M. Collazo, C. A. Corzo et al., “Regulatory myeloid suppressor cells in health and disease,” Cancer Research, vol. 69, no. 19, pp. 7503–7506, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Ostrand-Rosenberg, “Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity,” Cancer Immunology, Immunotherapy, vol. 59, no. 10, pp. 1593–1600, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Ostrand-Rosenberg and P. Sinha, “Myeloid-derived suppressor cells: linking inflammation and cancer,” Journal of Immunology, vol. 182, no. 8, pp. 4499–4506, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. I. R. Ramachandran, A. Martner, A. Pisklakova et al., “Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow,” Journal of Immunology, vol. 190, no. 7, pp. 3815–3823, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. G. T. Görgün, G. Whitehill, J. L. Anderson et al., “Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans,” Blood, vol. 121, no. 15, pp. 2975–2987, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. K. R. Muthu Raja, L. Kovarova, and R. Hajek, “Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma,” Leukemia & Lymphoma, vol. 53, no. 7, pp. 1406–1408, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. M. K. Brimnes, A. J. Vangsted, L. M. Knudsen et al., “Increased level of both CD4+FOXP3+ Regulatory t Cells and CD14+HLA-DR/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma,” Scandinavian Journal of Immunology, vol. 72, no. 6, pp. 540–547, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Lin, M. P. Gustafson, P. A. Bulur, D. A. Gastineau, T. E. Witzig, and A. B. Dietz, “Immunosuppressive CD14+HLA-DRlow/- monocytes in B-cell non-Hodgkin lymphoma,” Blood, vol. 117, no. 3, pp. 872–881, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. P. Serafini, I. Borrello, and V. Bronte, “Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression,” Seminars in Cancer Biology, vol. 16, no. 1, pp. 53–65, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. E. van Valckenborgh, E. Schouppe, K. Movahedi et al., “Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-Derived suppressor cell subpopulations in the bone marrow,” Leukemia, vol. 26, no. 11, pp. 2424–2428, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. L. Dolcetti, E. Peranzoni, S. Ugel et al., “Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF,” European Journal of Immunology, vol. 40, no. 1, pp. 22–35, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. J. Favaloro, T. Liyadipitiya, R. Brown et al., “Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma,” Leukemia & Lymphoma, 2014. View at Google Scholar
  96. L. Yang, L. M. DeBusk, K. Fukuda et al., “Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis,” Cancer Cell, vol. 6, no. 4, pp. 409–421, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. L. Yang, C. M. Edwards, and G. R. Mundy, “Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis,” Journal of Bone and Mineral Research, vol. 25, no. 8, pp. 1701–1706, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. A. Sawant, J. Deshane, J. Jules et al., “Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer,” Cancer Research, vol. 73, no. 2, pp. 672–682, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. C. Melani, S. Sangaletti, F. M. Barazzetta, Z. Werb, and M. P. Colombo, “Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma,” Cancer Research, vol. 67, no. 23, pp. 11438–11446, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. R. Wesolowski, J. Markowitz, and W. Carson, “Myeloid derived suppressor cells—a new therapeutic target in the treatment of cancer,” Journal For ImmunoTherapy of Cancer, vol. 1, no. 1, article 10, 2013. View at Google Scholar
  101. P. Serafini, K. Meckel, M. Kelso et al., “Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function,” Journal of Experimental Medicine, vol. 203, no. 12, pp. 2691–2702, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. L. Rudraraju, X. Ye, K. Noonan, C. A. Huff, and I. M. Borrello, “Administration of an oral PDE5 inhibitor, tadalafil In conjunction with a lenalidomide containing regimen in patients with multiple myeloma,” Blood, vol. 122, no. 21, article 1959, 2013. View at Google Scholar
  103. K. A. Noonan, N. Ghosh, L. Rudraraju, M. Bui, and I. Borrello, “Targeting immune suppression with PDE-5 inhibition in end stage multiple myeloma: a case study,” Cancer Immunology Research, 2014. View at Google Scholar
  104. N. Mitsiades, C. S. Mitsiades, V. Poulaki et al., “Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications,” Blood, vol. 99, no. 11, pp. 4079–4086, 2002. View at Publisher · View at Google Scholar · View at Scopus
  105. I. Sakamaki, L. W. Kwak, S.-C. Cha et al., “Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas,” Leukemia, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. L. Zitvogel, L. Galluzzi, M. Smyth, and G. Kroemer, “Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance,” Immunity, vol. 39, no. 1, pp. 74–88, 2013. View at Publisher · View at Google Scholar · View at Scopus
  107. P. Liu, J. Jaffar, I. Hellstrom, and K. E. Hellstrom, “Administration of cyclophosphamide changes the immune profile of tumor-bearing mice,” Journal of Immunotherapy, vol. 33, no. 1, pp. 53–59, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. A. Sistigu, S. Viaud, N. Chaput, L. Bracci, E. Proietti, and L. Zitvogel, “Immunomodulatory effects of cyclophosphamide and implementations for vaccine design,” Seminars in immunopathology, vol. 33, no. 4, pp. 369–383, 2011. View at Google Scholar · View at Scopus
  109. D. Alizadeh, M. Trad, N. T. Hanke et al., “Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T cell transfer in breast cancer,” Cancer Research, 2013. View at Google Scholar
  110. E. Terpos, J. Berenson, N. Raje, and G. D. Roodman, “Management of bone disease in multiple myeloma,” Expert Review of Hematology, vol. 7, no. 1, pp. 113–125, 2014. View at Google Scholar
  111. G. J. Morgan, F. E. Davies, W. M. Gregory et al., “Long-term follow-up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment,” Clinical Cancer Research, vol. 19, no. 21, pp. 6030–6038, 2013. View at Google Scholar
  112. A. Avilés, N. Neri, J. Huerta-Guzmán, and M. J. Nambo, “Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation,” Current Oncology, vol. 20, no. 1, pp. e13–e20, 2013. View at Publisher · View at Google Scholar · View at Scopus
  113. T. E. Witzig, K. M. Laumann, M. Q. Lacy et al., “A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma,” Leukemia, vol. 27, no. 1, pp. 220–225, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. M. R. Porembka, J. B. Mitchem, B. A. Belt et al., “Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth,” Cancer Immunology, Immunotherapy, vol. 61, no. 9, pp. 1373–1385, 2012. View at Publisher · View at Google Scholar · View at Scopus